Durata Report issue

Contributed to NME For profit Phase 3
Founded: Branford CT United States (2009)
Status: Acquired by Actavis (2014) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2013
NCT01946568
First Marketed Drug
2014
dalbavancin (dalvance)
First NDA Approval
2014
dalbavancin (dalvance)
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Durata Therapeutics

Active Ingredients

Marketed Drugs (1)

dalbavancin (dalvance) (2014 NDA)

Drugs in Phase 3 Trials (1)

dalbavancin (dalvance) (2 trials)

Indications

Approved Indications


 

Skin Diseases, Bacterial

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 1)

Cellulitis (Phase 3)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Surgical Wound Infection (Phase 3)

Wound Infection (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1